This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
RCE Technologies, Inc. RCE) is an innovative artificial intelligence (AI) based medical technology company dedicated to early heartattack detection. RCE) is an innovative artificial intelligence (AI) based medical technology company dedicated to early heartattack detection. Featured in an ACC.24
Caristo Diagnostics Limited has announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo's CaRi-Heart AI technology to quantify coronary artery inflammation and accurately predict cardiac events. Coronary inflammation is a crucial piece of the puzzle in predicting heartattack risk.
A therapy that has been proven repeatedly to reduce the probability of heartattacks and strokes in multiple double-blind randomised controlled studies 1. Additionally, access to cholesterol synthesis biomarker testing, including desmosterol and lathosterol levels, can be challenging to obtain. My approach for APOE 4 patients.
Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress. vs. 13.2%, respectively).
This misinformation would have resulted in many thousands of people giving up their medication and suffering heartattacks and strokes as a result. I, Dr Malcolm Kendrick, with or without other co-conspirators, would be accused of spreading misinformation about cholesterol and statins. With thousands dying.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content